Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change

Alzheimer Disease and Associated Disorders

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Schneider, Lon S ^a,b   Olin, Jason T ^b   Doody, Rachelle S ^c   Clark, Christopher M ^d   Morris, John C ^e   Reisberg, Barry ^f   Schmitt, Frederick A ^g   Grundman, Michael ^h   Thomas, Ronald G ^h   Ferris, Steven H ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; CGIC; Clinically relevant change; Severity scales

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RELIABILITY;

AGED; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030862602     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Berg L. Clinical dementia rating. Psychopharmacol Bull 1988;24: 637-9.
2. Boothby H. Measuring change in dementia: the reliability of clinical global assessments. In: Levy R, Howard R, eds. Developments in dementia and functional disorders in the elderly. Wrightson Biomedical Publishing, 1995:97-102.
3. Dahlke F, Lohaus A, Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 1992;28:425-32.
4. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
5. Ferris SH, Mackell JA, Mohs R, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S1-12 (this issue).
6. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
7. Guy W, ed. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976:218-22.
8. Kanowski S, Fischof P, Hiersemenzel R, Röhmel J, Kern U. Wirksamkeitsnachweis von nootropika am Beispiel von Nimodipin - ein Beitrag zur entwicklung geeigneter klinischer Prüfmodelle. Zeitschr Gerontopsychol Psychiatrie 1988;1:35-44.
9. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
10. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
11. Leber P. Unpublished letter to pharmaceutical companies [Issues affecting the implementation of the Clinician's Global Assessment]. November, 1991.
12. Lehmann E. Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales. Pharmacopsychiatry 1984;17:71-5.
13. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
14. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
15. Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457-65.
16. Olin JT, Schneider LS, Doody RS, et al. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol 1996;9:176-80.
17. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-9.
18. Reisberg B, Ferris SH, deLeon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
19. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
20. Schneider LS, Olin JT. Quantitative overview of the efficacy of Hydergine. Arch Neurol 1994;51:787-98.
21. Schneider LS, Olin JT. Clinical global impressions in clinical trials. Int J Psychogeriatr 1996;8:277-90.
22. Shader RL, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG). J Am Geriatr Soc 1974;22:107-13.
23. Stem RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatr 1994;151:390-6.
24. Stevens J. Applied multivariated statistics for the social sciences. Hillsdale, NJ: Lawrence Erlbaum, 1992.
25. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.